Details: pack, label wording, sources, registration
Vigamox 5 mg/ml, Eye drops
eye drops, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Topical treatment of a diagnosed or strongly suspected susceptible bacterial ocular-surface infection, including selected conjunctivitis and keratitis; viral, fungal, sterile and intraocular disease are outside scope
7.2/10
Good
Details →
vetman assessment
Vigamox
×
5 mg/ml, eye drops, human medicine
Assessed clinical scope Dog · Topical treatment of a diagnosed or strongly suspected susceptible bacterial ocular-surface infection, including selected conjunctivitis and keratitis; viral, fungal, sterile and intraocular disease are outside scope · Into the eye
Care setting Veterinary-directed ocular treatment after examination and fluorescein assessment, with culture and urgent ophthalmology escalation when severity or response requires it
vetman score
7.2/10
Good
Evidence confidence: Medium
Georgia: Yes, human · № რ-043040 · Verified on 22 Oct 2026
Off-label use
A credible off-label topical option for selected susceptible canine bacterial conjunctivitis or keratitis after ocular examination. Exact-product transparency and direct tear/susceptibility data support a good score; resistance, limited controlled outcome evidence and diagnosis-specific regimens prevent broader claims.
Regulatory and scientific credibility 8.0/10
The exact sterile 0.5% human ophthalmic product has a transparent FDA NDA/label and current Georgian and EU/EEA human registrations. Direct canine and feline ocular evidence supports a veterinary role, but it has no dog/cat authorisation and every assessed use is off-label.
Clinical efficacy 6.5/10
Exact-product tear PK confirms ocular exposure and tolerability in healthy dogs, and contemporary canine keratitis series show useful moxifloxacin susceptibility. Clinical-outcome evidence is mostly observational or multi-treatment, resistance and MDR are substantial, and prior fluoroquinolone exposure can raise MIC; diagnosis and culture matter more than broad empiric confidence.
Safety and tolerability 7.0/10
Topical exposure limits systemic burden and one exact-dose canine study found no ocular irritation, but diseased and repeatedly dosed eyes were not tested. Hypersensitivity, surface toxicity with very frequent use, contamination, resistant-organism or fungal overgrowth and delayed treatment of a deep/melting ulcer remain clinically important and require examination and early reassessment.
Clinical practicality 7.5/10
A ready sterile preservative-free drop needs no reconstitution, is simple to place and avoids systemic dosing calculations. Repeated restraint, strict tip hygiene, variable disease-specific frequency, culture/rechecks and urgent escalation for severe ulcers remain real professional workflow burdens, but they are proportionate to ocular infection management.
Full-course cost-effectiveness -
Current comparable local full-course prices and wastage after opening were not verified.
Important safety and use flags
This score covers only selected diagnosed or strongly suspected susceptible bacterial ocular-surface infection. It does not cover FHV-1, fungal keratitis, eosinophilic or sterile keratitis, corneal sequestrum, uveitis, glaucoma, dry eye alone or intraocular infection. Vigamox is a human medicine and all dog/cat use is off-label. Do not copy the human one-drop three-times-daily seven-day label as a universal veterinary regimen; site, depth, cytology, culture, severity and response determine the plan. Perform a complete ocular examination, fluorescein staining and corneal-depth assessment before treatment. Deep, melting or rapidly progressive ulcer, anterior uveitis, severe pain, vision loss, suspected penetration or absent early improvement requires urgent ophthalmology review and may need surgery or systemic treatment. Obtain cytology and culture with susceptibility testing before or promptly after starting therapy in deep, melting, recurrent, nosocomial, previously treated or poorly responding disease. Do not interpret historical aggregate susceptibility as proof that the current isolate is sensitive. Fluoroquinolone exposure can select resistant organisms and increased MIC has been documented after topical exposure. Reserve broad-spectrum moxifloxacin for a coherent indication, narrow or change treatment when results permit, and do not extend prophylaxis or treatment without reassessment. For ophthalmic use only. Never inject Vigamox into the eye or subconjunctivally; intraocular compounded moxifloxacin has separate formulation and toxicity concerns, and evidence for another vehicle or concentration cannot be transferred to this bottle. Stop and reassess for hypersensitivity or marked worsening. Prolonged use can permit non-susceptible bacterial or fungal overgrowth; new infiltrate, increasing discharge, stromal loss, greater pain or deterioration despite treatment is not a reason simply to increase frequency. Very frequent topical fluoroquinolone exposure can impair corneal epithelial healing and may promote melting. Intensive protocols may still be justified for a severe infected ulcer, but only with close veterinary or ophthalmology supervision; no universal maximum frequency is encoded here. Avoid contamination: wash hands, do not touch the tip to the eye, lashes, skin or fingers, recap promptly and do not share one bottle between patients or contaminated eyes. Discard a bottle with damaged seal, altered solution or suspected contamination. Record all concurrent ophthalmic products and separate drops by a practical interval so one does not wash out another; ointment is generally placed last. Review topical corticosteroids especially carefully: they are contraindicated with corneal ulceration and can worsen infection or melting. Assessment sources +
Close
Cat
Topical treatment of a diagnosed or strongly suspected susceptible bacterial ocular-surface infection, including selected conjunctivitis and keratitis; viral, fungal, sterile and intraocular disease are outside scope
7.0/10
Good
Details →
vetman assessment
Vigamox
×
5 mg/ml, eye drops, human medicine
Assessed clinical scope Cat · Topical treatment of a diagnosed or strongly suspected susceptible bacterial ocular-surface infection, including selected conjunctivitis and keratitis; viral, fungal, sterile and intraocular disease are outside scope · Into the eye
Care setting Veterinary-directed ocular treatment after examination and fluorescein assessment, with culture and urgent ophthalmology escalation when severity or response requires it
vetman score
7.0/10
Good
Evidence confidence: Medium
Georgia: Yes, human · № რ-043040 · Verified on 22 Oct 2026
Off-label use
A reasonable off-label topical option for selected susceptible feline bacterial ocular-surface infection, with useful in-vitro evidence but limited product-specific clinical outcomes. Confirm a bacterial component and do not let the drop substitute for antiviral, surgical or other disease-specific treatment.
Regulatory and scientific credibility 8.0/10
The exact sterile 0.5% human ophthalmic product has a transparent FDA NDA/label and current Georgian and EU/EEA human registrations. Direct canine and feline ocular evidence supports a veterinary role, but it has no dog/cat authorisation and every assessed use is off-label.
Clinical efficacy 6.0/10
A feline bacterial-keratitis series found high aggregate in-vitro moxifloxacin susceptibility, supporting it as a reasonable option when bacterial infection is likely. Product-specific feline cure trials are lacking, cohorts use multiple interventions, and common feline corneal disease may be viral or non-bacterial; susceptibility cannot be treated as guaranteed clinical cure.
Safety and tolerability 7.0/10
Topical exposure limits systemic burden and one exact-dose canine study found no ocular irritation, but diseased and repeatedly dosed eyes were not tested. Hypersensitivity, surface toxicity with very frequent use, contamination, resistant-organism or fungal overgrowth and delayed treatment of a deep/melting ulcer remain clinically important and require examination and early reassessment.
Clinical practicality 7.0/10
A ready sterile preservative-free drop needs no reconstitution or systemic dose calculation. Accurate placement may be harder in painful or poorly tolerant cats, while repeated restraint, strict tip hygiene, disease-specific frequency and short recheck intervals add burden; these are relevant clinical constraints rather than owner-convenience scoring alone.
Full-course cost-effectiveness -
Current comparable local full-course prices and wastage after opening were not verified.
Important safety and use flags
This score covers only selected diagnosed or strongly suspected susceptible bacterial ocular-surface infection. It does not cover FHV-1, fungal keratitis, eosinophilic or sterile keratitis, corneal sequestrum, uveitis, glaucoma, dry eye alone or intraocular infection. Vigamox is a human medicine and all dog/cat use is off-label. Do not copy the human one-drop three-times-daily seven-day label as a universal veterinary regimen; site, depth, cytology, culture, severity and response determine the plan. Perform a complete ocular examination, fluorescein staining and corneal-depth assessment before treatment. Deep, melting or rapidly progressive ulcer, anterior uveitis, severe pain, vision loss, suspected penetration or absent early improvement requires urgent ophthalmology review and may need surgery or systemic treatment. Obtain cytology and culture with susceptibility testing before or promptly after starting therapy in deep, melting, recurrent, nosocomial, previously treated or poorly responding disease. Do not interpret historical aggregate susceptibility as proof that the current isolate is sensitive. Fluoroquinolone exposure can select resistant organisms and increased MIC has been documented after topical exposure. Reserve broad-spectrum moxifloxacin for a coherent indication, narrow or change treatment when results permit, and do not extend prophylaxis or treatment without reassessment. For ophthalmic use only. Never inject Vigamox into the eye or subconjunctivally; intraocular compounded moxifloxacin has separate formulation and toxicity concerns, and evidence for another vehicle or concentration cannot be transferred to this bottle. Stop and reassess for hypersensitivity or marked worsening. Prolonged use can permit non-susceptible bacterial or fungal overgrowth; new infiltrate, increasing discharge, stromal loss, greater pain or deterioration despite treatment is not a reason simply to increase frequency. Very frequent topical fluoroquinolone exposure can impair corneal epithelial healing and may promote melting. Intensive protocols may still be justified for a severe infected ulcer, but only with close veterinary or ophthalmology supervision; no universal maximum frequency is encoded here. Avoid contamination: wash hands, do not touch the tip to the eye, lashes, skin or fingers, recap promptly and do not share one bottle between patients or contaminated eyes. Discard a bottle with damaged seal, altered solution or suspected contamination. Record all concurrent ophthalmic products and separate drops by a practical interval so one does not wash out another; ointment is generally placed last. Review topical corticosteroids especially carefully: they are contraindicated with corneal ulceration and can worsen infection or melting. Assessment sources +
Close
Administration route
Into the eye
Registration
Georgia
Yes, human
In force until 21 Mar 2028
Human (Ministry of Health, RAMA)
№ რ-043040
Verified on: 22 Oct 2026
EU
Yes, human
UK
No
US
Yes, human
№ NDA 021598
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified
For ophthalmic use only. No single universal dog/cat frequency is published here: bacterial conjunctivitis, superficial keratitis, deep or melting ulcer and postoperative prophylaxis require different diagnostic and monitoring decisions. Perform a full ocular examination and fluorescein assessment; use cytology/culture for severe, deep, melting, recurrent or previously treated disease. Do not touch the dropper tip to the eye or surrounding tissue.
